Cancer Epidemiology最新文献

{"title":"Impact of socioeconomic individual and ecological factors on extreme diagnosis-to-treatment interval in diffuse large B-Cell lymphoma in the French real-world cohort REALYSA","authors":"Christelle Cantrelle ,&nbsp;Aurélien Belot ,&nbsp;Alain Monnereau ,&nbsp;Fontanet Bijou ,&nbsp;Cédric Rossi ,&nbsp;Côme Bommier ,&nbsp;Hadia Khebbeb Hafirassou ,&nbsp;Ludovic Fouillet ,&nbsp;Hervé Ghesquières ,&nbsp;Loic Ysebaert ,&nbsp;Sandra Le Guyader Peyrou","doi":"10.1016/j.canep.2025.102875","DOIUrl":"10.1016/j.canep.2025.102875","url":null,"abstract":"<div><h3>Introduction</h3><div>Diffuse large B-cell lymphoma (DLBCL) is an aggressive though potentially curable lymphoid malignancy requiring timely treatment initiation. We investigated the impact of individual socioeconomic status and home area-level (ecological) factors on the diagnosis-to-treatment interval (DTI) in DLBCL patients, focusing on extreme delays in a French real-world cohort (REALYSA).</div></div><div><h3>Methods</h3><div>We analyzed patients with newly diagnosed DLBCL in the multicentric prospective cohort. DTI was defined as a duration in days between diagnosis confirmation and first-line therapy. Short and long DTIs (10th percentiles) were compared to intermediate DTI using multinomial models to identify factors associated with extreme DTIs. Socio-demographic data (including sex, education, employment, marital status, social support (SSQ6-score)…) and ecological characteristics (French deprivation index, local accessibility to general practitioners) were considered.</div></div><div><h3>Results</h3><div>Among 889 newly diagnosed DLBCL patients (median age 66 years, 49 % with aaIPI ≥1, 35 % with B-symptoms, 33 % with bulky disease), median DTI was 25 days (interquartile range: 15–39 days). The 10th- and 90th-percentile for extreme DTIs were &lt; 8 and &gt; 50 days respectively. In multivariable analysis, factors associated with short DTI included aaIPI (OR=3.03, CI95 %[1.44–6.41]), bulky disease (OR=3.06, CI95 %[1.68–5.58]), and B symptoms (OR=2.35, CI95 %[1.30–4.25]) - indicating expedited treatment for aggressive presentations. Conversely, factors associated with long DTI included older age (OR&gt;80 y = 3.31, CI95 %[1.39–7.89]), being a blue-collar worker or farmer (OR=2.36, CI95 %[1.18–4.73]), or changing type of treatment facility between biopsy and initial treatment.</div></div><div><h3>Conclusion</h3><div>In this large real-world cohort of newly diagnosed DLBCL patients, age, occupational status, and patients’ pathway were linked to very long delays to treatment. Interventions to streamline DTIs, especially for older and/or blue-collar or farmer patients, and for those changing facility of treatment, are warranted to improve quality of care.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"98 ","pages":"Article 102875"},"PeriodicalIF":2.3,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144829138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology and risk factors of invasive pulmonary fungal disease in patients with lung cancer","authors":"Lijuan Wang ,&nbsp;Kaiyao Jiang ,&nbsp;Meiyu Qu ,&nbsp;Zhiying Hao ,&nbsp;Yan Song ,&nbsp;Ruigang Hou","doi":"10.1016/j.canep.2025.102901","DOIUrl":"10.1016/j.canep.2025.102901","url":null,"abstract":"<div><h3>Background</h3><div>Patients with lung cancer exhibit heightened susceptibility to invasive pulmonary fungal diseases (IPFD) due to malignancy-associated immunosuppression. Current data on the pathogen distribution profile of IPFD in this population remain limited. This study investigated the epidemiological distribution of fungal pathogens causing IPFD in patients with lung cancer, with the aim of guiding clinical management.</div></div><div><h3>Methods</h3><div>We conducted a retrospective analysis of consecutive patients with lung cancer treated at the Second Hospital of Shanxi Medical University from June 2019 to May 2024. Patients were included if they had a discharge diagnosis of IPFD, received antifungal therapy, or presented microbiological evidence of fungal infection. All patients were diagnosed according to the 2007 Revised Consensus on Pulmonary Fungal Infections. Demographic, clinical, and laboratory data were collected. Univariate and multivariate logistic regression analyses were employed to identify independent IPFD risk factors.</div></div><div><h3>Results</h3><div>Of 1274 with lung cancer, 92 had proven or probable IPFD. <em>Candida spp</em>. (57.4 %) and <em>Aspergillus spp.</em> (35.3 %) were the predominant pathogens, with sputum (77.94 %), bronchoalveolar lavage fluid (17.65 %), and tissue (4.41 %) as specimen sources. Multivariate analysis identified the following independent risk factors for IPFD with lung cancer: hypertension (OR=5.08; 95 %CI: 1.41–18.28, P = 0.013), chronic respiratory diseases (OR=3.13; 95 %CI: 1.14–8.56, P = 0.026), bone marrow suppression (OR=2.72; 95 % CI: 1.17–6.33, P = 0.020), multiple comorbidities (OR=2.68; 95 % CI: 1.02–7.09, P = 0.046), and smoking (OR=2.47; 95 %CI: 1.08–5.64, P = 0.032).</div></div><div><h3>Conclusions</h3><div><em>Candida</em> and <em>Aspergillus</em> species were the most common causative agents of IPFD in patients with lung cancer. However, the emergence of less common fungi such as Geotrichum capitatum and Rhizopus microsporus, observed with increasing frequency in this study, warrants heightented clinical vigilance. Recognizing key risk factors, including chronic respiratory diseases, male sex, hypertension, multiple comorbidities and smoking, may guide early diagnosis and targeted antifungal therapy, ultimately improving clinical outcomes.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"98 ","pages":"Article 102901"},"PeriodicalIF":2.3,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144826661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Space-time dynamic variation trend of female breast cancer incidence and mortality: A global perspective (1990–2021)","authors":"Peichen Ke,&nbsp;Chunhui Li","doi":"10.1016/j.canep.2025.102898","DOIUrl":"10.1016/j.canep.2025.102898","url":null,"abstract":"<div><h3>Background</h3><div>Breast cancer is the most common malignant tumor affecting women, with significant space-time disparities in incidence and mortality, underscoring the importance of exploring its dynamic trends and clustering patterns.</div></div><div><h3>Methods</h3><div>The data were obtained from the Global Burden of Disease Study 2021. The study employed multiple spatial analytical methods to systematically examine the space-time distribution patterns of female breast cancer incidence and mortality worldwide. The Standard Deviational Ellipse method was used to track shifts in mean centers and directional trends, highlighting changes in spatial distribution over time. Building on this, spatial autocorrelation analysis measured the degree of overall spatial clustering as well as local cluster patterns at the national level. To further capture the space-time dynamics, Space-Time Scan Statistics was applied to detect statistically significant clustering regions across both space and time.</div></div><div><h3>Results</h3><div>From 1990–2021, global age-standardized incidence rate (ASIR) and age-standardized death rate (ASDR) peaked in 2019, then slightly declined before rising again. The spatial mean centers of ASIR and ASDR exhibited notable southeastward shifts, with ASIR's distribution contracting while ASDR remained stable, and the east-west directional trend of all ellipses was consistent. Persistent positive spatial autocorrelation was observed (Moran’s <em>I</em>: ASIR 0.28–0.39; ASDR 0.40–0.45; <em>p</em> &lt; 0.001). Local spatial autocorrelation analysis revealed that in 1990 and 2021, ASIR and ASDR exhibited significant spatial clustering characteristics in specific regions, particularly in Europe and Africa. High space-time clusters included ASIR centered in the UK (2015–2019, log likelihood ratio (LLR) = 735,045.42, relative risk (RR) = 2.72) and ASDR in Denmark (2015–2019, LLR = 207,088.37, RR = 2.55).</div></div><div><h3>Conclusion</h3><div>The study revealed the global space-time dynamics of female breast cancer, emphasizing disparities in medical resources, screening, and health policies.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"98 ","pages":"Article 102898"},"PeriodicalIF":2.3,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144769422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Childhood and adolescents’ cancer survival: Progress made and priorities for improvement. An Italian population-based study","authors":"Camilla Calì ,&nbsp;Rosalba Amodio ,&nbsp;Sabrina Fabiano ,&nbsp;Gemma Gatta ,&nbsp;Milena Maria Maule ,&nbsp;Viviana Perotti ,&nbsp;Fabio Savoia ,&nbsp;Marcella Sessa ,&nbsp;Andrea Tittarelli ,&nbsp;Walter Mazzucco ,&nbsp;Fabrizio Stracci ,&nbsp;Rosalia Ragusa ,&nbsp;AIRTUM Working Group","doi":"10.1016/j.canep.2025.102895","DOIUrl":"10.1016/j.canep.2025.102895","url":null,"abstract":"<div><h3>Background</h3><div>Population-based cancer registries are crucial to monitor health system performance, inform policy makers and allocate resources effectively. We updated Italian survival estimates for children and adolescents, analysing temporal and geographical differences to evaluate improvements.</div></div><div><h3>Methods</h3><div>Cases were from the Association of Italian Cancer Registries and codified according to the International Classification of Childhood Cancer, 3rd edition.</div><div>Thirty-one cancer registries provided 9142 incident cases (2013–2017) and 15 cancer registries contributed data for 12,447 incident cases (1998–2017) for trend analysis. We used the period approach to estimate survival in children (0–14 years) and adolescents (15–19 years) during the period 2013–2017. Survival was estimated by age, sex and geographical area of residence.</div></div><div><h3>Results</h3><div>Survival improved over time in both children and adolescents. Among children, significant progress was observed for acute myeloid leukaemia, non-Hodgkin lymphomas, ependymomas, Ewing sarcoma, and acute lymphoid leukaemia. For adolescents, notable improvements were found in non-Hodgkin lymphomas and skin melanomas. However, disparities emerged across Italy, with major differences observed for central nervous system neoplasms and osteosarcoma in children, as well as for acute lymphatic leukaemia and soft tissue sarcomas in adolescents.</div></div><div><h3>Conclusion</h3><div>Increased survival was observed in many Italian children and adolescents with tumours and differences emerged across Italian regions. We will investigate the reasons for these discrepancies in collaboration with clinicians.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"98 ","pages":"Article 102895"},"PeriodicalIF":2.3,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144738994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-diagnosis statin use and survival among lung cancer patients in the Military Health System","authors":"Jie Lin ,&nbsp;Robert F. Browning Jr. ,&nbsp;Craig D. Shriver ,&nbsp;Kangmin Zhu","doi":"10.1016/j.canep.2025.102897","DOIUrl":"10.1016/j.canep.2025.102897","url":null,"abstract":"<div><h3>Background</h3><div>There have been no studies examining the relationship between statin use and lung cancer survival in the U.S. Military Health System (MHS), a universal healthcare system. This study assessed whether statin use after lung cancer diagnosis is associated with overall survival among MHS beneficiaries with lung cancer.</div></div><div><h3>Methods</h3><div>This study was based on the Military Cancer Epidemiology (MilCanEpi) database, a database linking the DoD’s Central Cancer Registry (CCR) and the MHS Data Repository (MDR). The study subjects were MHS beneficiaries diagnosed with non-small cell lung cancer (NSCLC). Information on statin use was extracted from the database. Time-dependent Cox proportional hazard regression model was used to estimate hazard ratios (HRs) and 95 % confidence intervals (95 % CIs) comparing post-diagnosis use of statin relative to non-users.</div></div><div><h3>Results</h3><div>Among the 5096 patients, 864 patients used a statin after NSCLC diagnosis. Compared to individuals who never used statin, increased cumulative use of statin (per one-year of use) among the users conferred a significantly improved survival with an adjusted HR of 0.82 (95 % CI=0.75–0.90). In stratified analysis, the survival benefit or its tendency associated with increased cumulative use was observed regardless of age, race, sex, tumor stage, comorbidity index or baseline use.</div></div><div><h3>Conclusions</h3><div>Post-diagnosis statin use was associated with improved survival among NSCLC patients in a universal healthcare system.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"98 ","pages":"Article 102897"},"PeriodicalIF":2.3,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144725074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exposure to outdoor air pollution, wildfires, and cancer survival in the United States","authors":"Trang VoPham ,&nbsp;Tianjia Liu ,&nbsp;Malia Cortez ,&nbsp;Seigi Karasaki ,&nbsp;Nicholas F. Falkenberg ,&nbsp;Hiwot Y. Zewdie ,&nbsp;Jiayu Lin ,&nbsp;Caroline Nondin ,&nbsp;Sam L.S. Chao ,&nbsp;Tyler Knowlton ,&nbsp;Boris Quennehen ,&nbsp;Jason A. Mendoza ,&nbsp;George N. Ioannou ,&nbsp;Kristin Berry ,&nbsp;Gary Adamkiewicz ,&nbsp;Christopher I. Li ,&nbsp;Jaime E. Hart","doi":"10.1016/j.canep.2025.102899","DOIUrl":"10.1016/j.canep.2025.102899","url":null,"abstract":"<div><h3>Background</h3><div>Climate change has led to an increase in wildfires, a major source of air pollution, which may be particularly harmful to individuals diagnosed with cancer. The objective of this study was to examine the relationships of air pollution and wildfires with mortality risk among cancer survivors.</div></div><div><h3>Methods</h3><div>Surveillance, Epidemiology, and End Results (SEER) cancer registries provided information on 7,051,014 patients diagnosed with cancer from 2000 to 2021 in the United States. Cox regression was used to calculate adjusted hazard ratios (HRs) and 95 % confidence intervals (CIs) for the associations between exposures to particulate matter &lt; 2.5 µm (PM_2.5), nitrogen dioxide (NO₂), ozone (O₃), and wildfires (estimated using high-resolution geospatial datasets) with all-cause and cause-specific mortality risk.</div></div><div><h3>Results</h3><div>There were 3,452,593 deaths, including 2,369,364 from cancer, 525,409 from cardiopulmonary, and 557,820 from other causes. Among cancer survivors, higher exposure to PM_2.5 and wildfires (but not NO₂ or O₃) were associated with increased risk for all-cause, cancer, and other mortality. The association between PM_2.5 and cancer mortality was stronger in counties more heavily impacted by wildfires (HR per 10 μg/m³ in counties with ≥ median 0.39 wildfires per year: 1.17, 95 % CI 1.04–1.33) vs. no wildfires (HR 1.06, 95 % CI 0.97–1.15) (p interaction = 0.0064).</div></div><div><h3>Conclusions</h3><div>Among patients diagnosed with cancer, PM_2.5 air pollution, particularly in areas heavily impacted by wildfires, is associated with increased risk for mortality.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"98 ","pages":"Article 102899"},"PeriodicalIF":2.3,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144723300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time to non-small cell lung cancer treatment and impact on survival in West Virginia","authors":"Sabina Nduaguba ,&nbsp;Anna Lumadue ,&nbsp;Nicole Stout","doi":"10.1016/j.canep.2025.102894","DOIUrl":"10.1016/j.canep.2025.102894","url":null,"abstract":"<div><h3>Purpose</h3><div>To determine the time to treatment for patients with non-small cell lung cancer (NSCLC) in West Virginia (WV) by baseline characteristics and the association of timely treatment with survival.</div></div><div><h3>Methods</h3><div>A retrospective study was conducted using 1993–2021 WV Cancer Registry data to identify persons diagnosed with NSCLC who received treatment. Time to treatment from diagnosis was determined and dichotomized as early treatment (&lt;35 days) vs delayed treatment (≥35 days). Descriptive statistics, comparative and survival analyses (with univariate and multivariate Cox regression were used to address study objectives.</div></div><div><h3>Results</h3><div>Of 10,463 participants, the majority were male (58.1 %), married or partnered (59.9 %), non-Hispanic white (97.5 %). 61 % received early treatment. 45 %, 38 %, and 16 % received systemic therapy, surgery, and radiation, respectively.</div><div>Baseline characteristics significantly associated with treatment receipt included being male (HR=1.08, 95 % CI=1.04–1.13), cancer stage (HR range=1.19–2.38, being Black and receiving surgery (0.43, 0.30–0.62), radiation (0.48, 0.33–0.68), or systemic therapy (0.33,0.23–0.47) (compared to other treatment). Baseline characteristics significantly associated with death include rurality (HR=1.09, 95 % CI=1.00–1.18), age (HR=1.01, 1.01–1.02), male gender (HR=1.21 (1.16–1.26), being married (0.92, 0.88–0.96), comorbidity (1.07, 1.05–1.09), cancer stage (HR range=1.58–4.79), and receiving surgery (0.16, 0.11–0.22), radiation (0.34, 0.24–0.49), or systemic therapy (0.17, 0.12–0.24) (compared to other treatment).</div></div><div><h3>Conclusion</h3><div>In WV, most patients with NSCLC who receive treatment are treated early. Sociodemographic and clinical factors such as being male, cancer stage and type of treatment predicted time to treatment receipt and were likewise associated with overall survival. Cancer stage represents a modifiable factor that may be responsive to interventions aimed at improving lung cancer outcomes through early diagnosis.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"98 ","pages":"Article 102894"},"PeriodicalIF":2.4,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144712904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interleukin gene polymorphisms (IL1B, IL6, IL10, IL16, IL28B) increase prostate cancer risk and associate with aggressive disease features in Iraqi men: A case-control study","authors":"Wisam Hindawi Hoidy ,&nbsp;Mohammed Hamza Al-Saadi ,&nbsp;Simon Clegg","doi":"10.1016/j.canep.2025.102896","DOIUrl":"10.1016/j.canep.2025.102896","url":null,"abstract":"<div><h3>Background</h3><div>Prostate cancer is one of the most frequently diagnosed cancers in men globally. Chronic inflammation is a major contributor to the development of cancer, with interleukins as key players in regulating inflammatory pathways. This study aims to explore the association between IL1, IL6, IL10, IL16, and IL28 gene polymorphisms and the risk of prostate cancer in the Iraqi population.</div></div><div><h3>Methods</h3><div>This case-control study included 290 histologically confirmed prostate cancer patients and 350 age-matched healthy controls recruited from Al-Diwaniyah Teaching Hospital between February 2024 and December 2024. Genotyping for IL1B-511 C&gt;T (rs16944), IL6–174 G&gt;C (rs1800795), IL10–1082 A&gt;G (rs1800896), IL16–295 T &gt; C (rs4778889), and IL28B C&gt;T (rs12979860) polymorphisms was performed using tetra-primer amplification refractory mutation system-polymerase chain reaction (T-ARMS-PCR). Statistical analyses included odds ratios (ORs) with 95 % confidence intervals (CIs) and haplotype analysis.</div></div><div><h3>Results</h3><div>Significant associations with prostate cancer risk were observed for the IL1B-511 TT genotype (OR=1.76, 95 % CI: 1.18–2.63, p = 0.006), IL6–174 GG genotype (OR=1.66, 95 % CI: 1.12–2.45, p = 0.011), IL10–1082 GG genotype (OR=1.82, 95 % CI: 1.20–2.76, p = 0.005), IL16–295 CC genotype (OR=1.88, 95 % CI: 1.27–2.79, p = 0.002), and IL28B TT genotype (OR=1.79, 95 % CI: 1.22–2.63, p = 0.003). Haplotype analysis revealed that the TGGCT haplotype was associated with a 2.35-fold increased risk of prostate cancer (OR=2.35, 95 % CI: 1.51–3.66, p &lt; 0.001). Stratified analyses demonstrated stronger associations between these polymorphisms and aggressive disease characteristics, including higher Gleason scores, advanced tumor stages, and elevated PSA levels.</div></div><div><h3>Conclusion</h3><div>In this study, we identified proliferative inflammatory lesions of the prostate in Iraqi patients, suggesting that polymorphisms in the IL1B, IL6, IL10, IL16, and IL28B genes significantly increased prostate cancer risk and exacerbated aggressive disease features. These findings suggest the key role of these gene variants in modulating inflammatory and immune responses in the prostate carcinogenesis. Additional research is necessary to investigate these findings in other populations and examine the possibility of using them as risk assessment and personalized treatment biomarkers.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"98 ","pages":"Article 102896"},"PeriodicalIF":2.4,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144711673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and survival outcomes of adult T-cell leukemia/lymphoma in Latin America: A multicenter cohort study and recommendations to improve diagnosis and outcomes","authors":"Bryan Valcarcel ,&nbsp;Henry Idrobo ,&nbsp;Astrid Pavlovsky ,&nbsp;Eliana C.M. Miranda ,&nbsp;Brady Beltran ,&nbsp;Sally Paredes ,&nbsp;Daniel Enriquez-Vera ,&nbsp;Jule F. Vasquez ,&nbsp;Claudia Roche ,&nbsp;Fabiola Valvert ,&nbsp;Luis Villela ,&nbsp;Thais Fischer ,&nbsp;Juliana Pereira ,&nbsp;Renata L.R. Baptista ,&nbsp;Guilherme Duffles ,&nbsp;Sergio A.B. Brasil ,&nbsp;Carolina Oliver ,&nbsp;Jamila Vaz Tavares ,&nbsp;Karin Z. Cecyn ,&nbsp;Danielle L.C. De Farias ,&nbsp;Luis Malpica","doi":"10.1016/j.canep.2025.102890","DOIUrl":"10.1016/j.canep.2025.102890","url":null,"abstract":"<div><h3>Background</h3><div>Although adult T-cell leukemia/lymphoma (ATL) has a higher burden in Latin America compared to North American or European countries, few studies have described the outcomes of this disease. We estimated the hospital-based prevalence and overall survival (OS) of ATL.</div></div><div><h3>Methods</h3><div>We conducted a cohort study among patients aged ≥ 18 years with pathologically diagnosed mature T-cell lymphoma across 11 Latin American countries from 2000 to 2023 by pooling data from 3 hospital-based registries. We used the Kaplan-Meier method to estimate survival outcomes.</div></div><div><h3>Results</h3><div>Among 1963 patients with mature T-cell lymphoma, the pooled prevalence of ATL was 17 % (n = 329; 95 % confidence interval [CI]=15–18 %), with the highest observed in Peru (n = 158; 38 %, 95 % CI=33–43 %) and Colombia (n = 17; 29 %, 95 % CI=18–41 %). Over time, ATL cases only increased significantly in Peru, from 14 % in 2000–2004 to 58 % in 2019–2023 (P_{<em>trend</em>}&lt;0.001). With a median follow-up of 37 months (95 % CI=30–54 months), the 3-year OS of ATL was 25 % (95 % CI=20–32 %), and the median OS was 9 months (95 % CI=8–12 months). OS did not differ across countries (range 19–47 %, P = 0.210). Patients with lymphomatous ATL had worse outcomes than those with PTCL-NOS only in Peru (P_{<em>heterogeneity</em>}=0.029).</div></div><div><h3>Conclusion</h3><div>Our findings indicate a higher ATL prevalence in Latin America than previously reported in North America or Europe, likely due to differences in HTLV-1 endemicity and diagnostic practices. The similar and poor survival rates across countries underscore the need for targeted interventions to improve patient outcomes. We propose expert-based research priorities and suggest further epidemiological validation studies.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"98 ","pages":"Article 102890"},"PeriodicalIF":2.4,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144711672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer incidence, mortality, and survival estimates in Italy: Methodological approaches","authors":"Maria Teresa Pesce ,&nbsp;Paolo Contiero ,&nbsp;Carlotta Buzzoni ,&nbsp;Sabrina Fabiano ,&nbsp;Alessio Gili ,&nbsp;Andrea Tittarelli ,&nbsp;Viviana Perotti ,&nbsp;Riccardo Capocaccia ,&nbsp;Fabrizio Stracci ,&nbsp;Walter Mazzucco ,&nbsp;Maurizio Zarcone ,&nbsp;AIRTUM Working Group","doi":"10.1016/j.canep.2025.102891","DOIUrl":"10.1016/j.canep.2025.102891","url":null,"abstract":"<div><div>Italy, home to one of the world’s oldest populations, has traditionally shown geographic differences in cancer incidence, with rates decreasing from north to south. The cancer registries that have been accredited by the Italian Cancer Registry Network (AIRTUM), during the last 20 years altogether cover the 90 % of the Italian population, aiming to improve data quality, standardize procedures, and promote research. This study presents the methodological approaches used for data collection, quality control, and analysis to describe current patterns of cancer incidence, mortality, and survival across Italy's three macro-areas (North, Central, South). Estimates of incidence rates and case numbers for 2025 were also produced. Data from 34 accredited cancer registries were analyzed, comprising over 4.6 million cases from 1981 to 2020, with a detailed focus on the 2008–2017 period, which includes over 3 million cases. Cancer incidence and mortality data were collected according to ICD-O-3 and ICD-10 classifications and processed for statistical analysis using tools such as SEER<em>Prep, SEER</em>Stat, and the Joinpoint Regression Program. Age-standardized rates were calculated, and incidence and mortality trends from 2013 to 2017 were modeled. Five-year cumulative net survival was estimated using the Pohar-Perme method to adjust for competing risks. Survival trends were analyzed by geographic areas and cancer sites, revealing regional disparities in cancer outcomes.</div></div>","PeriodicalId":56322,"journal":{"name":"Cancer Epidemiology","volume":"98 ","pages":"Article 102891"},"PeriodicalIF":2.4,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144703261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}